Regenicin Inc (RGIN) Return on Equity ROE from the second quarter 2023 to second quarter 2022 and annually, average high and low, overall ranking from Mar 31 2023 to Mar 31 2022 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Regenicin Inc   (RGIN)

Regenicin Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Regenicin Inc in the second quarter 2023?
Due to the lack of equity, it was not possible to calculate Regenicin Inc 's return on equity (ROE) in its second quarter 2023

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2023)
II. Quarter		 (Dec 31 2022)
I. Quarter		 (Sep 30 2022)
IV. Quarter		 (Jun 30 2022)
III. Quarter		 (Mar 31 2022)
II. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -1 -1 -1 -1 -1
Return On Equity (TTM) - - - - -
RGIN's Total Ranking # # # # #
Equity (TTM) in Millions -6 -6 -6 -5 -5
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to RGIN Management Effectiveness >> RGIN's 5 Years Annual ROE >> Compare RGIN ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





RGIN Annual Return On Equity (Sep 30 2022)
2022		 (Sep 30 2021)
2021		 (Sep 30 2020)
2020		 (Sep 30 2019)
2019		 (Sep 30 2018)
2018
Total Equity in Millions -6 -5 -4 -4 -3
Y / Y Equity Change - - - - -
Net Income in Millions -1 -1 -1 -1 1
Y / Y Net Income Change - - - - 1579.26 %
Return On Equity - - - - -

Back to RGIN Management Effectiveness >> RGIN's 5 Years Annual ROE >> Compare RGIN ROE to its Competitors




Annual Roe Comment
In 2022 ROE improved to 1579.26 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Medical Equipment & Supplies Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
RGIN's' Return on Equity at Yahoo Finance
RGIN's Roe Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for RGIN's Competitors
Subscribers only: Roe for Regenicin Inc 's Suppliers
Subscribers only: Return On Equity for RGIN's Customers




Companies with similar Return On Equity at Mar 31 2023, within Healthcare Sector ROE
Zoetis Inc   45.61 %
Dynavax Technologies Corporation  45.58 %
Nrc Health  42.71 %
Tenet Healthcare Corp  42.11 %
Maravai Lifesciences Holdings Inc   40.04 %
3m Company  37.66 %
Innoviva Inc   37.23 %
Catalyst Pharmaceuticals Inc   34.72 %
Chemed Corporation  31.06 %
Pfizer Inc  30.83 %
Bruker Corporation  29.49 %
Ironwood Pharmaceuticals inc   29.31 %
Semler Scientific inc   28.98 %
Merck and Co Inc   28.84 %
Carlisle Companies Incorporated  27.74 %
Oncotelic Therapeutics Inc   27.58 %
Pro dex Inc   26.83 %
Gilead Sciences Inc   26.56 %
Point Biopharma Global Inc   26.47 %
Zynex inc   26.02 %
Moderna Inc   25.87 %
Agilent Technologies inc   25.16 %
Edwards Lifesciences Corporation  24.78 %
Resmed Inc   24.50 %
Vertex Pharmaceuticals Inc  24.46 %
Biogen Inc   24.17 %
Bristol myers Squibb Company  22.83 %
Puma Biotechnology Inc   21.52 %
West Pharmaceutical Services Inc   21.32 %
Escalon Medical Corp   21.09 %

Date modified: 2026-09-08T15:10:57+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.